NCT05474664

Camostat Mesylate for Protein-losing Enteropathy After Fontan Operation

Phase 2 Open-label, Single-arm, Multi-center Clinical Trial to Evaluate the Efficacy and Safety of Camostat Mesylate in Patients with Protein-losing Enteropathy After Fontan Operation

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 19 (actual)
• Sponsor: Seoul National University Hospital · Academic / Other
• Sex: All
• Age: 4 Years
• Healthy volunteers: Not accepted

Summary

This study is phase 2 open-label, single-arm, multi-center clinical trial to evaluate the efficacy and safety of Camostat mesylate in patients with Protein-losing enteropathy after Fontan operation.

Conditions

• Fontan Operation
• Protein-Losing Enteropathy
• Camostat Mesylate

Interventions

Type	Name	Description
DRUG	Camostat mesylate	1. 4\~12 years old: Camostate mesylate 100 mg, 2 times a day 2. greater than 13 years old: Camostate mesylate 100 mg, 3 times a day

Timeline

• Start date: 2022-10-03
• Primary completion: 2024-07-12
• Completion: 2024-10-08
• First posted: 2022-07-26
• Last updated: 2024-12-03

Locations

1 site across 1 country: South Korea